The designation is based, in part, on positive data from AbbVie's clinical development program, including the Phase 2b clinical trial M11-652, known as "Aviator." The Aviator study was conducted in 571 patients infected with HCV GT1.
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/AbbVies-Investigational-HCV-Regimen-Receives-Break/ArticleNewsFeed/Article/detail/812443?ref=25
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/AbbVies-Investigational-HCV-Regimen-Receives-Break/ArticleNewsFeed/Article/detail/812443?ref=25
No comments:
Post a Comment